anergic

Anergy has two major USMLE-relevant contexts: (1) Clinical anergy: inability to mount a delayed-type hypersensitivity (Type IV) reaction to a recall antigen skin test (e.g., PPD/tuberculin, Candida, mumps). This occurs in severely immunocompromised patients (advanced HIV/AIDS with low CD4 counts, malnutrition, sarcoidosis, overwhelming infection like miliary TB, or immunosuppressive therapy). Clinically important because a negative PPD in an anergic patient does NOT rule out TB infection—false negative result. Anergy panels (testing response to multiple recall antigens) were historically used to confirm functional T-cell immunity before interpreting a negative PPD. (2) Immunologic/clonal anergy: a peripheral tolerance mechanism in which T cells (or B cells) become functionally inactivated after encountering antigen without proper costimulation (signal 2, e.g., CD28-B7 interaction). Without costimulation, even strong TCR-MHC engagement (signal 1) leads to a non-responsive state rather than activation—this prevents autoimmunity by inactivating self-reactive T cells that escape central tolerance in the thymus. Anergic T cells remain alive but cannot proliferate or produce IL-2 upon subsequent antigen exposure. This mechanism is tested in context of transplant immunology, autoimmune disease pathogenesis, and immune checkpoint biology (related conceptually to CTLA-4, which also dampens T-cell activation). Key associations: HIV/AIDS progression, sarcoidosis (anergy despite granulomatous inflammation), overwhelming sepsis, and the two-signal hypothesis of T-cell activation.